These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Internalization of radioiodinated erythropoietin and the ligand-induced modulation of its receptor in murine erythroleukemia cells. Fukamachi H; Tojo A; Saito T; Kitamura T; Nakata M; Urabe A; Takaku F Int J Cell Cloning; 1987 May; 5(3):209-19. PubMed ID: 3474303 [TBL] [Abstract][Full Text] [Related]
10. Purification of murine erythropoietin produced in serum-free cultures of erythroleukemia cells. Qian RL; Chin K; Kim JK; Chin HM; Cone J; Hankins WD Blood; 1986 Jul; 68(1):258-62. PubMed ID: 3459556 [TBL] [Abstract][Full Text] [Related]
11. Abnormal erythropoietin (Epo) gene expression in the murine erythroleukemia IW32 cells results from a rearrangement between the G-protein beta2 subunit gene and the Epo gene. Chrétien S; Duprez V; Maouche L; Gisselbrecht S; Mayeux P; Lacombe C Oncogene; 1997 Oct; 15(16):1995-9. PubMed ID: 9365246 [TBL] [Abstract][Full Text] [Related]
12. The biochemistry of erythropoietin: an approach to its mode of action. Sytkowski AJ; McIntyre CJ; Perrine SP; Salvado AJ Exp Hematol; 1980; 8 Suppl 8():52-64. PubMed ID: 6962071 [TBL] [Abstract][Full Text] [Related]
13. Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity. Murate T; Yamashita K; Ohashi H; Kagami Y; Tsushita K; Kinoshita T; Hotta T; Saito H; Yoshida S; Mori KJ Exp Hematol; 1993 Jan; 21(1):169-76. PubMed ID: 8417953 [TBL] [Abstract][Full Text] [Related]
14. Activation of the erythropoietin gene in the majority of F-MuLV-induced erythroleukemias results in growth factor independence and enhanced tumorigenicity. Howard JC; Berger L; Bani MR; Hawley RG; Ben-David Y Oncogene; 1996 Apr; 12(7):1405-15. PubMed ID: 8622856 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib. Cervi D; Truong AH; Lee JS; Sukhai N; Li YJ; Koki A; Ben-David Y Oncogene; 2004 Mar; 23(13):2305-14. PubMed ID: 14743207 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205 [TBL] [Abstract][Full Text] [Related]
17. Antipeptide antibodies as probes of the recombinant and endogenous murine erythropoietin receptors. Bailey SC; Feldman L; Romanowski RR; Davis KL; Sytkowski AJ Exp Hematol; 1993 Nov; 21(12):1535-43. PubMed ID: 7691637 [TBL] [Abstract][Full Text] [Related]
18. Growth and differentiation of human and murine erythroleukemia cell lines in serum-free synthetic medium. Pessano S; McNab A; Rovera G Cancer Res; 1981 Sep; 41(9 Pt 1):3592-6. PubMed ID: 7020933 [TBL] [Abstract][Full Text] [Related]
19. Ligand binding kinetics of a soluble full-length murine erythropoietin receptor. Avedissian LS; Poola I; Spivak JL Biochem Biophys Res Commun; 1995 Nov; 216(1):62-8. PubMed ID: 7488125 [TBL] [Abstract][Full Text] [Related]
20. An anticancer drug-sensitive murine erythroleukemia clone: implications for the mechanism of action of antineoplastic drugs. Dinnen RD; Robinow CF; Ebisuzaki K Cancer Res; 1993 Apr; 53(8):1877-82. PubMed ID: 8467509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]